35 min
Game Changing New Medication for Hot Flashes with Dr. Nanette Santoro HOT FLASHES & COOL TOPICS
-
- Self-Improvement
This week is a "game" changer episode. For those who watched the Super Bowl, you may have noticed a commercial asking women what is "VMS"? None could answer but the commercial was actually promoting awareness for vasomotor symptoms (a/k/a hot flashes and night sweats).
Astellas Pharmaceuticals paid for this advertisement because it has a non- hormonal medication currently in Phase 3 trials with the FDA. The medication is called Fezolinetant and is a neuron inhibitor that will hopefully improve menopausal symptoms for women with moderate to severe hot flashes.
Our guest this week is Dr. Nanette Santoro, a professor and E. Stewart Taylor Chair of Obstetrics & Gynecology at the University of Colorado School of Medicine and a reproductive endocrinologist specializing in menopause. Dr. Santoro is also on the Board of Review for Astellas and has written several research papers on this new medication.
She explains what benefits fezolinetant will offer as a non-hormonal options for moderate to severe hot flashes, how it works and if approved by the FDA, how long will it take to get to market.
Listen to this episode and subscribe to the podcast on any podcast platform. You will find all the links from this episode in our show notes on our website.
www.hotflashescooltopics.com
This week is a "game" changer episode. For those who watched the Super Bowl, you may have noticed a commercial asking women what is "VMS"? None could answer but the commercial was actually promoting awareness for vasomotor symptoms (a/k/a hot flashes and night sweats).
Astellas Pharmaceuticals paid for this advertisement because it has a non- hormonal medication currently in Phase 3 trials with the FDA. The medication is called Fezolinetant and is a neuron inhibitor that will hopefully improve menopausal symptoms for women with moderate to severe hot flashes.
Our guest this week is Dr. Nanette Santoro, a professor and E. Stewart Taylor Chair of Obstetrics & Gynecology at the University of Colorado School of Medicine and a reproductive endocrinologist specializing in menopause. Dr. Santoro is also on the Board of Review for Astellas and has written several research papers on this new medication.
She explains what benefits fezolinetant will offer as a non-hormonal options for moderate to severe hot flashes, how it works and if approved by the FDA, how long will it take to get to market.
Listen to this episode and subscribe to the podcast on any podcast platform. You will find all the links from this episode in our show notes on our website.
www.hotflashescooltopics.com
35 min